Safety, tolerability, and serum/tear pharmacokinetics of human
recombinant epidermal growth factor eyedrops in healthy subjects
Hyounggyoon Yoo1,6, Seonghae
Yoon1,4, In-Jin Jang1,3, Kyung-Sang
Yu1,3, Joon Young Hyon2,5, Jungi
Hwang7, Inyoung Hwang1,3, Jung
Sunwoo1,3, Jae-Yong Chung1,4
1. Department of Clinical Pharmacology and Therapeutics, Seoul National
University College of Medicine, Seoul, Republic of Korea
2. Department of Ophthalmology, Seoul National University College of
Medicine, Seoul, Republic of Korea
3. Department of Clinical Pharmacology and Therapeutics, Seoul National
University Hospital, Seoul, Republic of Korea
4. Department of Clinical Pharmacology and Therapeutics, Seoul National
University Bundang Hospital, Seongnam, Republic of Korea
5. Department of Ophthalmology, Seoul National University Bundang
Hospital, Seongnam, Republic of Korea
6. Department of Clinical Pharmacology and Therapeutics, CHA Bundang
Medical Center, Seongnam, Republic of Korea
7. Department of Clinical Pharmacology and Therapeutics, Chungbuk
National University Hospital, Cheongju, Republic of Korea
*The authors confirm that the Principal Investigator
for this paper is Jae-Yong Chung and that he had direct clinical
responsibility for study participants.